P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM...

Autor MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, N Rabin, RZ Orlowski, K Suzuki, T Plesner, SS Yoon, D Ben Yehuda, PG Richardson, H Goldschmidt, D Reece, T Ahmadi, X Qin, W Garvin Mayo, X Gai, J Carey, R Carson, P Moreau
Vydáno 2022-04-01

B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Autor F Gay, JG Berdeja, V De Stefano, P Hari, B Hooper, A Haltner, S Kumar, T Martin, M-V Mateos, P Moreau, E Rosta, IA Samjoo, SZ Usmani, K Weisel, CC Jackson, Y Olyslager, JM Schecter, M Vogel, A Garrett, S Lee, T Nesheiwat, L Pacaud, C Zhou, S Valluri, LJ Costa, Y Lin
Vydáno 2022-04-01

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS

Autor M Mateos, P Hari, N Bahlis, A Chari, NWCJ van de Donk, B Dholaria, AL Garfall, H Goldschmidt, KM Kortüm, A Krishnan, T Martin, D Morillo, A Oriol, D Reece, C Rodriguez, P Rodríguez-Otero, JF San-Miguel, SZ Usmani, R Verona, SXW Lin, TJ Prior, M Wade, B Weiss, JD Goldberg, E Askari
Vydáno 2022-04-01